Speculation regarding a potential fundraise
31 January 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising.
Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price. Any fundraise would include an open offer to accommodate retail investors.
As per the announcement of 19 January, the Company has significant cash resources. Accordingly, there is no immediate need to raise additional capital and the Company may choose not to proceed with a fundraising until such time as conditions are more favourable.
A further announcement will be made in due course as necessary.
|Omega Diagnostics Group PLC||www.omegadx.com|
|Jag Grewal, Chief Executive Officer||via Walbrook PR|
|Chris Lea, Chief Financial Officer|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)||Alice Lane/ Charlotte Sutcliffe (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Applegarth||Mob: 07584 391 303|
|Sam Allen||Mob: 07502 558 258|
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.